

Supporting Information

Cao et al. 10.1073/pnas.1114368109

SI Experimental Procedures

DNA Constructs. Full-length human *dlc1* cDNA (GenBank accession number NM_006094) was generated by RT-PCR from total RNA of MCF10A cells and subcloned into a eukaryotic expression vector, pcDNA3.1(+) (Invitrogen) with FLAG tag at the C terminus, via the NheI and XbaI restriction sites. The truncated fragments of deleted in liver cancer 1 (DLC1), DLC1-sterile alpha motif (SAM), DLC1-ΔSAM, DLC1-rhodopsin-GTPase-activating (Rho-GAP)-steroidogenic acute regulatory protein-related lipid transfer (START), DLC1-Rho-GAP, and DLC1-START, were generated by PCR from the full-length pcDNA3.1(+)-DLC1-FLAG. Full-length human *tensin3* (GenBank accession number NM_006094) and *cten* (GenBank accession number AF417489) cDNA were generated by RT-PCR from total RNA of MCF10A cells and subcloned into the eukaryotic expression vector, pEGFPC3 (Clontech), using BglII and Sall sites or BglII and EcoRI sites. The truncated fragments of *tensin3* [tensin3 actin-binding domain (ABD) and *tensin3*ΔABD] were generated by PCR from full-length pEGFPC3-*tensin3*. The SAM domain of DLC1 was amplified by PCR from full-length pcDNA3.1(+)-DLC1-FLAG and subcloned via the BamHI/XhoI sites into a pGEX6P3 (GE Healthcare) vector. All constructs were verified by DNA sequencing.

Reagents and Antibodies. Unless indicated, chemical reagents were purchased from Sigma-Aldrich. Glutathione Sepharose 4 Fast Flow was purchased from GE Healthcare. Anti-DLC1 rabbit polyclonal antibody, anti-DLC1 goat polyclonal antibody, anti-*tensin3* goat polyclonal antibody, anti-paxillin rabbit polyclonal antibody, anti-RhoA rabbit polyclonal antibody, anti-GFP rabbit polyclonal antibody, anti-GST rabbit polyclonal antibody, and anti-β-tubulin rabbit polyclonal antibody were purchased from Santa Cruz Biotech. Anti-Tns3 (*tensin3*) rabbit polyclonal antibody, anti-COOH-terminal *tensin*-like protein (*cten*) mouse monoclonal antibody, and anti-FLAG mouse monoclonal antibody were obtained from Sigma-Aldrich. Antiactive RhoA-GTP mouse monoclonal antibody was from NewEast Biosciences. Anti-phosphotyrosine mouse monoclonal antibody (4G10) was purchased from Upstate Tech. Anti-Akt rabbit polyclonal antibody, anti-Phospho-AKT (Ser473) mouse monoclonal antibody, anti-p44/42 MAPK (ERK1/2) mouse monoclonal antibody, and anti-Phospho-p44/42 MAPK (Thr202/Tyr204) mouse monoclonal antibody were from Cell Signaling Technologies. Anti-epidermal growth factor receptor rabbit polyclonal antibody was from Millipore.

Cell Culture, Transfection, and Inhibitor Treatment. HEK293, A549, and MCF10A cells were obtained from American Type Culture Collection. HEK293 and A549 cells were maintained in DMEM containing antibiotics and 10% FBS (Sigma). MCF10A cells full medium contains DMEM:F12 (1:1) medium supplemented with antibiotics, EGF (10 ng/mL), insulin (10 μg/mL), cholera toxin (1 μg/mL), hydrocortisone (1 μg/mL), and heat-inactivated horse serum (5%) (Invitrogen). MCF10A cells serum-starved medium contains no horse serum and EGF. MCF10A cells EGF treatment medium contains no horse serum. MCF10A cells transfection medium contains no antibiotics. Cells were incubated at 37°C in a humidified 5% CO₂ atmosphere. Transient transfections were carried out with jet polyethylenimine according to the manufacturer's instructions. Rho-associated protein kinase (ROCK)-specific inhibitor Y27632 was obtained from Calbiochem. For treatment, cells were incubated with 10 μM Y27632 for 1 h at 37°C.

Bacterial Expression of Recombinant Proteins and GST Pull-down. The BL21 strain of *Escherichia coli* was transformed with pGEX6P3-DLC1-SAM or empty vector and induced with 0.1 mM IPTG for 16 h at 18°C. The bacterial cultures were harvested and pellets were resuspended in PBS containing complete protease inhibitors (Roche). The suspension was sonicated for three times (10 s each) on ice. Triton X-100 was added to a final concentration of 1% and the lysates were centrifuged at 15,700 × g for 15 min under 4°C. Purification of GST-tagged proteins was performed with glutathione resin (GE Healthcare). The resin was washed with PBS for three times. The purity of the proteins was determined by SDS-PAGE followed by Coomassie staining. Pull-down was performed by incubating whole cell lysates with GST-DLC1-SAM or GST beads for 3 h, followed by washing the beads with lysis buffer for three times at 4°C as described (1). Proteins that bound to GST or GST-SAM were resolved on SDS-PAGE and identified by Western blot analysis.

Lysate Preparation, Immunoprecipitation, and Western Blotting. HEK293, A549, and MCF10A cells were lysed with cold lysis buffer (1% Nonidet P-40, 50 mM Tris pH 7.4, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, 10% glycerol, and protease inhibitor cocktail diluted at 1:1,000). To prepare MCF10A cell lysates, cell pellets were sonicated in 0.2 mL lysis buffer on ice, and the lysate was spun down at 15,700 × g for 15 min at 4°C (Centrifuge 5415R; Eppendorf). The supernatants were collected and the protein concentrations of the lysates were determined using the Bio-Rad Protein Assay Kit. After clearance of the lysate with appropriate preimmune serum and protein G (Roche), immunoprecipitation was performed using indicated antibodies following established protocols (2). Western blotting was carried out as described previously (2).

RNA Preparation and Real-Time RT-PCR analysis. Total RNA was extracted by QIAGEN RNeasy Mini Kit (74104), and the reverse transcription reaction was performed using QIAGEN QuantiTect Reverse Transcription Kit (205311) following the manufacturer's protocol. After mixing the resulting template with FastStart SYBR Green Master (04673492001; Roche) and indicated primers as below, the real-time RT-PCR reaction was performed with the Stratagene Mx3005P QPCR System (QIAGEN-SABiosciences) using protocols as described previously (3, 4).

DLC1 Forward Primer: 5'-ggatggatgaggagaagctgaa-3'
DLC1 Reverse Primer: 5'-ggctcgcgtggagttggaaa-3'
cten Forward Primer: 5'-cccaccatgaagttcgtgatg-3'
cten Reverse Primer: 5'-cggtatgaagactgtcccttatg-3'
tensin3 Forward Primer: 5'-gttgaagggtgctcgaatga-3'
tensin3 Reverse Primer: 5'-gaactttctgtatttctccaatg-3'
tensin1 Forward Primer: 5'-gtgcaaggaggactgaattcg-3'
tensin1 Reverse Primer: 5'-ggctacaagactctccaagtgg-3'
tensin2 Forward Primer: 5'-cctccagccccgagaagatc-3'
tensin2 Reverse Primer: 5'-tgctggttgagttctcatagag-3'
β-tubullin Forward Primer: 5'-aacacggatgagactactgcat-3'
β-tubulin Reverse Primer: 5'-gggtgceggaagcagatgt-3'

Knockdown of Protein Expression by siRNA. siRNA oligonucleotides specific for human *cten* (5) were synthesized by GenePharma. siCten-I: 5'-UUCUCAUUGACAUGGUGCUCUGGGC-3'; siCten-II: 5'-GGAGGAAUCUGAAGCCUUGGACAU-3'. siRNA oligos targeting *dlc1* (sc-43725) and the control siRNA (sc-44236) were obtained from Santa Cruz Biotech. The acces-

Table S2. Changes in gene expression for DLC1, tensin family members, and the ErbB family receptors between 111 breast cancer samples and 12 normal breast samples

Gene	Normal	SD	Tumor	SD	Fold change	<i>p</i> value
DLC1	-0.80	0.81	0.33	0.42	1.13	1.36E-12
cten	-0.22	2.08	1.30	0.91	1.52	7.57E-06
tensin3	0.22	1.44	-0.84	0.60	-1.06	3.56E-06
tensin2	0.34	1.34	-0.74	0.46	-1.08	2.76E-08
tensin1	0.18	0.38	-0.08	0.34	-0.26	0.01
ErbB2	0.08	2.60	2.84	1.22	2.76	1.91E-09
ErbB4	0.24	0.79	1.17	0.76	0.93	0.00

Analysis was done using the microarray data of Finak et al. (1). Specifically, the gene expression data of 111 breast stroma collected from breast cancer patients and 12 normal breast stroma samples, were obtained from the National Center for Biotechnology Information Gene Expression Omnibus database under the accession number GSE9014. Comparisons of mean values and standard deviations between the normal and breast stroma groups were analyzed using Excel. Statistical significance of the differences was analyzed using unpaired Student's *t* test.

1. Finak, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. *Nat Med* 14:518–527.